Healthcare Market Research Company in Brazil

BioNixus provides primary healthcare market research in Brazil across five practice areas: (1) HCP and KOL research — quantitative physician surveys and qualitative depth interviews across oncology, cardiovascular, diabetes, immunology, and infectious disease; (2) patient and caregiver research — LGPD-compliant patient journey mapping and treatment experience studies with CEP ethics clearance under Resolution CNS 510/2016; (3) medical devices research — RDC 751/2022 risk-class-aware study design, SUS tender research, and private hospital procurement mapping; (4) SUS and CONITEC access research — evidence supporting incorporation submissions and PCDT protocol proposals; and (5) ANS private-sector research — supplementary insurance market analysis across the 50 million Brazilians covered by private health plans.

Brazil's healthcare market is estimated at approximately USD 155-175 billion in 2026 — the largest in Latin America and among the ten largest globally. The market operates on two parallel channels: SUS (Sistema Único de Saúde), the universal public healthcare system serving 170+ million citizens, and the ANS-regulated private supplementary insurance sector (Agência Nacional de Saúde Suplementar) covering approximately 50 million Brazilians at international price points and roughly 35% of total healthcare spending. The pharmaceutical market is approximately USD 26-30 billion and the medical devices market approximately USD 11-13 billion.

ANVISA (Agência Nacional de Vigilância Sanitária) is the federal regulator for both pharmaceuticals and medical devices in Brazil. Medical device registration is governed by RDC 751/2022, which establishes four risk classes (I through IV) with escalating technical documentation requirements. ANVISA registration is mandatory before any product can be commercialized in Brazilian territory. For non-promotional scientific market research, ANVISA does not prohibit HCP engagement, but BioNixus aligns all recruitment materials with the ANVISA promotional code and INTERFARMA self-regulatory guidance.

SUS (Sistema Único de Saúde) is Brazil's universal public healthcare system, serving the majority of the population and requiring CONITEC (Comissão Nacional de Incorporação de Tecnologias no SUS) health technology assessment for reimbursement decisions — research here focuses on formulary committee priorities, PCDT protocol gaps, and budget-impact evidence from a public-payer perspective. ANS (Agência Nacional de Saúde Suplementar) regulates the private supplementary insurance sector covering roughly 50 million Brazilians through premium hospital networks (Hospital Albert Einstein, Hospital Sírio-Libanês, BP – A Beneficência Portuguesa, Mater Dei) at international price points. BioNixus designs distinct research tracks for each channel since decision-makers, evidence requirements, and pricing dynamics differ materially between them.

The largest therapy areas for healthcare market research in Brazil are: (1) Oncology — Brazil has the highest cancer incidence in Latin America, with SUS expanding INCA-affiliated cancer centre protocols and growing biosimilar/targeted-therapy adoption; (2) Diabetes — Brazil has approximately 16 million diagnosed diabetic patients, the sixth-largest diabetic population globally, with GLP-1 agonists and SGLT-2 inhibitors growing fastest in the private ANS sector; (3) Cardiovascular disease — the highest-volume chronic therapy area, generic-dominant but with branded opportunity in newer anticoagulants; (4) Immunology and biologics — TNF, IL-17, and JAK inhibitors growing in private supplementary insurance alongside accelerating ANVISA-approved biosimilar adoption; and (5) Infectious disease, anchored by Brazil's globally recognized SUS-funded HIV/ARV programme.

BioNixus HCP and KOL recruitment in Brazil combines Conselho Federal de Medicina (CRM) registry validation, academic hospital network access (Hospital das Clínicas USP, INCA, Hospital Albert Einstein, Hospital Sírio-Libanês), specialty society lists across SBC (cardiology), SBOC (oncology), SBD (diabetes), and SBI (infectious disease), digital professional panels with credentialing checks, and peer-referral sampling for hard-to-reach specialties. Patient and caregiver recruitment runs through hospital partner networks and patient associations under CEP ethics clearance, with all data processing LGPD-compliant (Lei Geral de Proteção de Dados, Law 13.709/2018).

Yes. While São Paulo and Rio de Janeiro concentrate the largest prescriber and premium-hospital populations, BioNixus recruits regionally across the Nordeste, Centro-Oeste, and Sul regions, with post-stratification weighting based on IBGE census data by region and income quintile — avoiding the common bias of treating São Paulo–Rio findings as nationally representative.

Yes. Brazil and the GCC share structural parallels — large public/centralized procurement systems (SUS/NUPCO), sizable generics markets, and premium private hospital sectors — that make cross-regional expansion strategy natural. BioNixus delivers SFDA (Saudi Arabia), MOHAP (UAE), and MOH (Kuwait, Qatar, Oman) regulatory intelligence, NUPCO tender and hospital formulary data, and Arabic/English HCP research from our regional offices, alongside comparative Brazil-GCC benchmarking for companies sequencing launches across both regions.